172 related articles for article (PubMed ID: 34113545)
21. Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux-Lamy syndrome).
Lin HY; Huang YH; Lei SY; Chen LJ; Lin SP
Taiwan J Ophthalmol; 2019; 9(3):194-197. PubMed ID: 31572657
[TBL] [Abstract][Full Text] [Related]
22. Current diagnosis and management of mucopolysaccharidosis VI in the Asia-Pacific region.
Hwu WL; Okuyama T; But WM; Estrada S; Gu X; Hui J; Kosuga M; Lin SP; Ngu LH; Shi H; Tanaka A; Thong MK; Wattanasirichaigoon D; Wasant P; McGill J
Mol Genet Metab; 2012 Sep; 107(1-2):136-44. PubMed ID: 22864057
[TBL] [Abstract][Full Text] [Related]
23. Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome).
Quartel A; Hendriksz CJ; Parini R; Graham S; Lin P; Harmatz P
JIMD Rep; 2015; 18():1-11. PubMed ID: 25518809
[TBL] [Abstract][Full Text] [Related]
24. Cerebral magnetic resonance findings during enzyme replacement therapy in mucopolysaccharidosis.
Matsubara Y; Miyazaki O; Kosuga M; Okuyama T; Nosaka S
Pediatr Radiol; 2017 Nov; 47(12):1659-1669. PubMed ID: 28733853
[TBL] [Abstract][Full Text] [Related]
25. Therapy for the mucopolysaccharidoses.
Valayannopoulos V; Wijburg FA
Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
[TBL] [Abstract][Full Text] [Related]
26. Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries.
Magner M; Almássy Z; Gucev Z; Kieć-Wilk B; Plaiasu V; Tylki-Szymańska A; Zafeiriou D; Zaganas I; Lampe C
Orphanet J Rare Dis; 2022 May; 17(1):190. PubMed ID: 35538504
[TBL] [Abstract][Full Text] [Related]
27. Addressing the need for patient-friendly medical communications: adaptation of the 2019 recommendations for the management of MPS VI and MPS IVA.
Bruce IA; Ezgü FS; Kampmann C; Kenis V; Mackenzie W; Stevens B; Walker R; Hendriksz C
Orphanet J Rare Dis; 2022 Mar; 17(1):91. PubMed ID: 35236367
[TBL] [Abstract][Full Text] [Related]
28. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
[TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America.
Solano M; Fainboim A; Politei J; Porras-Hurtado GL; Martins AM; Souza CFM; Koch FM; Amartino H; Satizábal JM; Horovitz DDG; Medeiros PFV; Honjo RS; Lourenço CM
Mol Genet Metab Rep; 2020 Jun; 23():100572. PubMed ID: 32140416
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study.
Ficicioglu C; Matalon DR; Luongo N; Menello C; Kornafel T; Degnan AJ
Orphanet J Rare Dis; 2020 Nov; 15(1):336. PubMed ID: 33256811
[TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement therapy: efficacy and limitations.
Concolino D; Deodato F; Parini R
Ital J Pediatr; 2018 Nov; 44(Suppl 2):120. PubMed ID: 30442189
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy.
Garcia P; Phillips D; Johnson J; Martin K; Randolph LM; Rosenfeld H; Harmatz P
Mol Genet Metab; 2021 May; 133(1):100-108. PubMed ID: 33775523
[TBL] [Abstract][Full Text] [Related]
33. Comparison of growth dynamics in different types of MPS: an attempt to explain the causes.
Różdżyńska-Świątkowska A; Zielińska A; Tylki-Szymańska A
Orphanet J Rare Dis; 2022 Sep; 17(1):339. PubMed ID: 36064607
[TBL] [Abstract][Full Text] [Related]
34. Medical Costs Related to Enzyme Replacement Therapy for Mucopolysaccharidosis Types I, II, and VI in Brazil: A Multicenter Study.
Bitencourt FH; Vieira TA; Steiner CE; Neto JC; Boy R; Schwartz IVD
Value Health Reg Issues; 2015 Dec; 8():99-106. PubMed ID: 29698178
[TBL] [Abstract][Full Text] [Related]
35. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.
Muñoz-Rojas MV; Horovitz DD; Jardim LB; Raymundo M; Llerena JC; de Magalhães Tde S; Vieira TA; Costa R; Kakkis E; Giugliani R
Mol Genet Metab; 2010 Apr; 99(4):346-50. PubMed ID: 20036175
[TBL] [Abstract][Full Text] [Related]
36. Integrated Management of an Adult Patient with Mucopolysaccharidosis type IVA: A Case Report with a Six-Year Follow-up.
Vergatti A; Abate V; Della Monica M; De Filippo G; Rendina D; Barbato A
Eur J Case Rep Intern Med; 2024; 11(1):004113. PubMed ID: 38223275
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of sleep-disordered breathing and its relationship with respiratory parameters in children with mucopolysaccharidosis Type IVA and VI.
Ademhan Tural D; Emiralioglu N; Dogru D; Ozsezen B; Ipek OF; Sunman B; Nayir Buyuksahin H; Guzelkas I; Ciki K; Kilic K; Vardar Yagli N; Yalcin E; Kiper N; Sivri S; Ozcelik U
Am J Med Genet A; 2021 Aug; 185(8):2306-2314. PubMed ID: 33960649
[TBL] [Abstract][Full Text] [Related]
38. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
[TBL] [Abstract][Full Text] [Related]
39. [Mucopolysaccharidosis: clinical features, diagnosis and management].
Suarez-Guerrero JL; Gómez Higuera PJ; Arias Flórez JS; Contreras-García GA
Rev Chil Pediatr; 2016; 87(4):295-304. PubMed ID: 26613630
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers in patients with mucopolysaccharidosis type II and IV.
Fujitsuka H; Sawamoto K; Peracha H; Mason RW; Mackenzie W; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
Mol Genet Metab Rep; 2019 Jun; 19():100455. PubMed ID: 30775257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
